Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury

Matrix Biology

Volumn 35, Issue , 2014, Pages 143-151

  Moreth, Kristin ^a,c   Frey, Helena ^a   Hubo, Mario ^a   Zeng Brouwers, Jinyang ^a   Nastase, Madalina Viviana ^a   Hsieh, Louise Tzung Harn ^a   Haceni, Riad ^a   Pfeilschifter, Josef ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Institute of Experimental Genetics and the German Mouse Clinic   (Germany)

Author keywords

Danger signal; Extracellular matrix; Inflammation; Innate immunity; Proteoglycan; Toll like receptor

Indexed keywords

ALKALINE PHOSPHATASE; BIGLYCAN; CHEMOKINE; CXCL1 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; BGN PROTEIN, MOUSE; CYTOKINE; PRIMER DNA; TLR2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE NECROSIS; MOUSE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; T LYMPHOCYTE; ANIMAL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MUS;

ACUTE KIDNEY INJURY; ANIMALS; BIGLYCAN; BLOTTING, WESTERN; CHEMOKINES; CYTOKINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84901429117     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2014.01.010     Document Type: Article

References (45)

1. Allam R., Scherbaum C.R., Darisipudi M.N., Mulay S.R., Hägele H., Lichtnekert J., Hagemann J.H., Rupanagudi K.V., Ryu M., Schwarzenberger C., Hohenstein B., Hugo C., Uhl B., Reichel C.a., Krombach F., Monestier M., Liapis H., Moreth K., Schaefer L., Anders H.-J. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J. Am. Soc. Nephrol. 2012, 23:1375-1388.
2. Arumugam T.V., Okun E., Tang S.-C., Thundyil J., Taylor S.M., Woodruff T.M. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16.
3. Babelova A., Moreth K., Tsalastra-Greul W., Zeng-Brouwers J., Eickelberg O., Young M.F., Bruckner P., Pfeilschifter J., Schaefer R.M., Gröne H.-J., Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009, 284:24035-24048.
4. Bonventre J.V., Yang L. Science in medicine cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 2011, 121:4210-4221.
5. Brandan E., Gutierrez J. Role of skeletal muscle proteoglycans during myogenesis. Matrix Biol. 2013, 32:289-297.
6. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants?. J. Leukoc. Biol. 2010, 87:989-999.
7. Frey H., Schroeder N., Manon-jensen T., Iozzo R.V., Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013, 280:2165-2179.
8. Furuichi K., Wada T., Yokoyama H., Kobayashi K. Role of cytokines and chemokines in renal ischemia-reperfusion injury. Drugs News Perspect. 2002, 15:477-482.
9. Groeneveld T.W.L., Oroszlán M., Owens R.T., Faber-krol M.C., Bakker A.C., Arlaud G.J., Mcquillan D.J., Kishore U., Daha M.R., Roos A., Oroszla M., Arlaud J. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J. Immunol. 2005, 175:4715-4723.
10. Hassan I.R., Gronert K., Alerts E. Acute changes in dietry w-3 and w-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemia renal injury and formation of renoprotective docosahexaenoic acid-derived protectin d1. J. Immunol. 2009, 182:3223-3232.
11. Iozzo R.V., Karamanos N. Proteoglycans in health and disease: emerging concepts and future directions. FEBS J. 2010, 277:3863.
12. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010, 277:3864-3875.
13. Iozzo R.V., Goldini S., Berendsen A., Young M.F. Small leucine-rich proteoglycans. The Extracellular Matrix: An Overview 2011, 197-231. Springer. R.P. Mecham (Ed.).
14. Iyer S.S., Pulskens W.P., Sadler J.J., Butter L.M., Teske G.J., Ulland T.K., Eisenbarth S.C., Florquin S., Flavell R.a., Leemans J.C., Sutterwala F.S. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20388-20393.
15. Krüger B., Krick S., Dhillon N., Lerner S.M., Ames S., Bromberg J.S., Lin M., Walsh L., Vella J., Fischereder M., Krämer B.K., Colvin R.B., Heeger P.S., Murphy B.T., Schröppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3390-3395.
16. Leemans J.C., Stokman G., Claessen N., Rouschop K.M., Teske G.J.D., Kirschning C.J., Akira S., van der Poll T., Weening J.J., Florquin S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 2005, 115:2894-2903.
17. Li L., Huang L., Sung S.-S.J., Vergis A.L., Rosin D.L., Rose C.E., Lobo P.I., Okusa M.D. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 2008, 74:1526-1537.
18. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhão J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
19. Merline R., Nastase M.-V., Iozzo R.V., Schaefer L. Small Leucine-rich proteoglycans: multifunctional signaling effectors. Extracellular Matrix: Pathobiology and Signaling 2012, 185-196. Walter de Gruytier GmbH & Co., Berlin. N. Karamanos (Ed.).
20. Mittag D., Proietto A.I., Loudovaris T., Mannering S.I., Vremec D., Shortman K., Wu L., Harrison L.C. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J. Immunol. 2011, 186:6207-6217.
21. Moreth K., Brodbeck R., Babelova A., Gretz N., Spieker T., Zeng-brouwers J., Pfeilschifter J., Young M.F., Schaefer R.M., Schaefer L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest. 2010, 120:4251-4272.
22. Munshi R., Hsu C., Himmelfarb J. Advances in understanding ischemic acute kidney injury. BMC Med. 2011, 9:11.
23. Newton K., Dixit V.M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 2012, 4.
24. Nikitovic D., Aggelidakis J., Young M.F., Iozzo R.V., Karamanos N.K., Tzanakakis G.N. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 2012, 287:33926-33933.
25. Oh D., Dursun B., He Z., Lu L., Hoke T.S., Ljubanovic D., Faubel S., Edelstein C.L. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am. J. Ren. Physiol. 2008, 294:264-271.
26. Park P., Haas M., Cunningham P.N., Bao L., Alexander J.J., Quigg R.J. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am. J. Physiol. Renal Physiol. 2002, 282:F352-F357.
27. Parroche P., Lauw F.N., Goutagny N., Latz E., Monks B.G., Visintin A., Halmen K.a., Lamphier M., Olivier M., Bartholomeu D.C., Gazzinelli R.T., Golenbock D.T. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1919-1924.
28. Patschan D., Patschan S., Müller G.A. Inflammation and microvasculopathy in renal ischemia reperfusion injury. J. Transplant 2012, 764154. 10.1155/2012/764154.
29. Popovic Z.V., Wang S., Papatriantafyllou M., Kaya Z., Porubsky S., Meisner M., Burgdorf S., Young M.F. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J. Immunol. 2011, 187:6217-6226.
30. Pulskens W.P., Teske G.J., Butter L.M., Roelofs J.J., van der Poll T., Florquin S., Leemans J.C. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One 2008, 3:e3596.
31. Rabb H., Daniels F., O'Donnell M., Haq M., Saba S.R., Keane W., Tang W.W. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am. J. Physiol. Renal Physiol. 2000, 279:F525-F531.
32. Rusai K., Sollinger D., Baumann M., Wagner B., Strobl M., Schmaderer C., Roos M., Kirschning C., Heemann U., Lutz J. Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr. Nephrol. 2010, 25:853-860.
33. Rutnam Z.J., Wight T.N., Yang B.B. miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol. 2013, 32:74-85.
34. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr. Opin. Pharmacol. 2010, 10:185-190.
35. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J. Am. Soc. Nephrol. 2011, 22:1200-1207.
36. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
37. Schaefer L., Raslik I., Gröne H., Schönherr K., Ugorcakova J., Budny S., Schaefer R.M., Kresse H. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J. 2001, 15:559-561.
38. Schaefer L., Babelova A., Kiss E., Hausser H., Baliova M., Krzyzankova M., Marsche G., Young M.F., Mihalik D., Götte M., Malle E., Schaefer R.M., Gröne H. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:26-28.
39. Shigeoka A.A., Holscher T.D., King A.J., Hall F.W., Kiosses W.B., Tobias P.S., Mckay D.B., Mackman N. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-Dependent and -independent pathways. J. Immunol. 2013, 178:6252-6258.
40. Stroo I., Stokman G., Teske G.J.D., Raven A., Butter L.M., Florquin S., Leemans J.C. Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase. Int. Immunol. 2010, 22:433-442.
41. Swaminathan S., Griffin M.D. First responders: understanding monocyte-lineage traffic in the acutely injured kidney. Kidney Int. 2008, 74:1509-1511.
42. Wienken C.J., Baaske P., Rothbauer U., Braun D., Duhr S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 2010, 1:100.
43. Wu H., Chen G., Wyburn K.R., Yin J., Bertolino P., Eris J.M., Alexander S.I., Sharland A.F., Chadban S.J. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 2007, 117:2847-2859.
44. Wu H., Ma J., Wang P., Corpuz T.M., Panchapakesan U., Wyburn K.R., Chadban S.J. HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc. Nephrol. 2010, 21:1878-1890.
45. Zeng-Brouwers J., Beckmann J., Nastase M.-V., Iozzo R.V., Schaefer L. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. Matrix Biol. 2014, 35:132-142.